Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
TSC2
MCID: TBR026
MIFTS: 67

Tuberous Sclerosis 2 (TSC2)

Categories: Fetal diseases, Genetic diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Tuberous Sclerosis 2

About this section

MalaCards integrated aliases for Tuberous Sclerosis 2:

Name: Tuberous Sclerosis 2 57 12 75 29 6 15 73
Tuberous Sclerosis, Type 2 76 53 40
Tsc2 Angiomyolipomas, Renal, Modifier of 57 6
Tuberous Sclerosis-2 57 13
Tuberous Sclerosis 75 73
Tsc2 57 75
Tuberous Sclerosis Complex 75
Ts 75

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant

Miscellaneous:
majority of cases are sporadic
highly variable phenotype
genetic heterogeneity (see )
one-third of cases are familial
prevalence of 1 in 6,000 to 1 in 10,000
many studies have reported that the phenotype of tuberous sclerosis-2 (tsc2) is more severe than that of tuberous sclerosis-1 (e.g., lower iq, more seizures, more macules, cust-like cortical tubers)
frequent new mutations (~60%) and/or gonadal mosaicism in tsc2


HPO:

32
tuberous sclerosis 2:
Onset and clinical course phenotypic variability
Inheritance heterogeneous autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Fetal diseases
Anatomical: Neuronal diseases Skin diseases Nephrological diseases Respiratory diseases
See all MalaCards categories (disease lists)


Sources

Summaries for Tuberous Sclerosis 2

About this section
OMIM : 57 Tuberous sclerosis complex (TSC) is an autosomal dominant multisystem disorder characterized by hamartomas in multiple organ systems, including the brain, skin, heart, kidneys, and lung. These changes can result in epilepsy, learning difficulties, behavioral problems, and renal failure, among other complications (reviews by Crino et al., 2006 and Curatolo et al., 2008). For a general phenotypic description and a discussion of genetic heterogeneity of tuberous sclerosis, see tuberous sclerosis-1 (191100), caused by mutation in the TSC1 gene (605284) on chromosome 9q34. Approximately 10 to 30% of cases of tuberous sclerosis are due to mutations in the TSC1 gene: the frequency of cases due to mutations in the TSC2 gene is consistently higher. TSC2 mutations are associated with more severe disease (Crino et al., 2006) (see GENOTYPE/PHENOTYPE CORRELATIONS section). (613254)

MalaCards based summary : Tuberous Sclerosis 2, also known as tuberous sclerosis, type 2, is related to polycystic kidney disease, infantile severe, with tuberous sclerosis and subependymal giant cell astrocytoma, and has symptoms including seizures, tremor and back pain. An important gene associated with Tuberous Sclerosis 2 is TSC2 (TSC Complex Subunit 2), and among its related pathways/superpathways are Akt Signaling and Human cytomegalovirus infection. The drugs Everolimus and Sirolimus have been mentioned in the context of this disorder. Affiliated tissues include skin, brain and kidney, and related phenotypes are hypothyroidism and precocious puberty

Disease Ontology : 12 A tuberous sclerosis that is characterized by hamartomas in multiple organ systems and has material basis in heterozygous mutation in the TSC2 gene on chromosome 16p13.

UniProtKB/Swiss-Prot : 75 Tuberous sclerosis 2: An autosomal dominant multi-system disorder that affects especially the brain, kidneys, heart, and skin. It is characterized by hamartomas (benign overgrowths predominantly of a cell or tissue type that occurs normally in the organ) and hamartias (developmental abnormalities of tissue combination). Clinical manifestations include epilepsy, learning difficulties, behavioral problems, and skin lesions. Seizures can be intractable and premature death can occur from a variety of disease-associated causes.

Wikipedia : 76 Tuberous sclerosis, or tuberous sclerosis complex (TSC), or epiloia (acronym of "epilepsy, low... more...

Sources

Related Diseases for Tuberous Sclerosis 2

About this section

Diseases in the Tuberous Sclerosis family:

Tuberous Sclerosis 1 Tuberous Sclerosis 2

Diseases related to Tuberous Sclerosis 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 404)
# Related Disease Score Top Affiliating Genes
1 polycystic kidney disease, infantile severe, with tuberous sclerosis 32.7 PKD1 TSC2
2 subependymal giant cell astrocytoma 32.6 MTOR TSC1 TSC2
3 tuberous sclerosis 1 32.0 MTOR TSC1 TSC2
4 focal cortical dysplasia, type ii 32.0 MTOR TSC1 TSC2
5 familial adenomatous polyposis 3 31.8 NTHL1 TSC2
6 polycystic kidney disease 1 with or without polycystic liver disease 31.7 MTOR PKD1 TSC1 TSC2
7 lissencephaly with cerebellar hypoplasia 31.6 TSC1 TSC2
8 kidney benign neoplasm 31.6 MTOR TSC2
9 subependymal glioma 31.6 MTOR TSC1 TSC2
10 benign ependymoma 31.6 MTOR TSC1 TSC2
11 benign glioma 31.6 MTOR TSC1 TSC2
12 adult hepatocellular carcinoma 31.5 TSC1 TSC2
13 polycystic liver disease 1 with or without kidney cysts 31.4 PKD1 TSC1 TSC2
14 angiomyolipoma 31.3 MTOR TSC1 TSC2
15 kidney angiomyolipoma 31.2 MTOR TSC1 TSC2
16 congenital heart defects, hamartomas of tongue, and polysyndactyly 30.5 TSC1 TSC2
17 tuberous sclerosis 30.5 IRS1 MTOR NTHL1 PKD1 TSC1 TSC2
18 renal cell carcinoma, nonpapillary 30.5 IFNG MTOR TSC1 TSC2
19 hepatic angiomyolipoma 30.3 MTOR TSC2
20 polycystic kidney disease 30.0 MTOR PKD1 TSC2
21 cystic kidney disease 30.0 PKD1 TSC1 TSC2
22 lymphangioleiomyomatosis 29.9 MTOR TSC1 TSC2
23 focal epilepsy 29.9 MTOR TSC1 TSC2
24 autosomal dominant polycystic kidney disease 29.7 IGF1 MTOR PKD1 TSC1 TSC2
25 diabetes mellitus 28.9 IFNG IGF1 IRS1 KCNA2 MTOR
26 gilles de la tourette syndrome 12.1
27 turner syndrome 11.9
28 virus-associated trichodysplasia spinulosa 11.7
29 lennox-gastaut syndrome 11.6
30 insulinoma 11.5
31 hereditary renal cell carcinoma 11.3
32 renal oncocytoma 11.2
33 timothy syndrome 11.2
34 trichostasis spinulosa 11.2
35 temperature sensitivity complementation, cell cycle specific, k12 11.2
36 spinal cancer 11.1
37 autosomal dominant café au lait spots 11.1
38 pilocytic astrocytoma 11.1
39 soft tissue sarcoma 11.1
40 brain and spinal tumors 11.1
41 cowden syndrome 1 11.1
42 von hippel-lindau syndrome 11.1
43 polycystic kidney disease 4 with or without polycystic liver disease 11.1
44 cowden disease 11.1
45 albinism, oculocutaneous, type ib 11.0
46 corneal dystrophy, fleck 11.0
47 neuroblastoma 11.0
48 central nervous system benign neoplasm 11.0
49 uterine benign neoplasm 11.0
50 nervous system benign neoplasm 11.0

Graphical network of the top 20 diseases related to Tuberous Sclerosis 2:



Diseases related to Tuberous Sclerosis 2
Sources

Symptoms & Phenotypes for Tuberous Sclerosis 2

About this section

Symptoms via clinical synopsis from OMIM:

57
Endocrine Features:
hypothyroidism
precocious puberty

Neurologic Behavioral Psychiatric Manifestations:
autism
hyperactivity
attention deficit disorder

Head And Neck Eyes:
achromatic retinal patches
retinal astrocytoma
optic gliomas

Neoplasia:
ependymoma
renal carcinoma
myocardial rhabdomyoma
multiple bilateral renal angiomyolipoma
giant cell astrocytoma
more
Head And Neck Mouth:
pitted dental enamel
gingival fibroma

Skeletal:
cystic areas of bone rarefaction, esp. phalanges

Neurologic Central Nervous System:
seizures
infantile spasms
subependymal nodules
hamartomatous lesions of the brain
cortical tubers
more
Skin Nails Hair Skin:
shagreen patch
subcutaneous nodules
cafe-au-lait spots
facial angiofibroma (adenoma sebaceum)
white ash leaf-shaped macules
more
Cardiovascular Heart:
cardiac rhabdomyoma
wolf-parkinson-white syndrome

Genitourinary Kidneys:
renal cysts
tumors of the kidney (may progress to malignancy in less than 2%)

Respiratory Lung:
lymphangiomyomatosis, rare

Laboratory Abnormalities:
increased frequency of premature centromere disjunction (pcd) in cultured fibroblasts, esp. chromosome 3
allelic loss on 16p13.3 in angiomyolipoma, cardiac rhabdomyoma, cortical tuber, and giant cell astrocytoma


Clinical features from OMIM:

613254

Human phenotypes related to Tuberous Sclerosis 2:

32 (show all 27)
# Description HPO Frequency HPO Source Accession
1 hypothyroidism 32 HP:0000821
2 precocious puberty 32 HP:0000826
3 intellectual disability 32 very rare (1%) HP:0001249
4 seizures 32 HP:0001250
5 cerebral calcification 32 HP:0002514
6 subcutaneous nodule 32 HP:0001482
7 autism 32 HP:0000717
8 attention deficit hyperactivity disorder 32 HP:0007018
9 specific learning disability 32 HP:0001328
10 wolff-parkinson-white syndrome 32 HP:0001716
11 renal cell carcinoma 32 HP:0005584
12 astrocytoma 32 HP:0009592
13 infantile spasms 32 HP:0012469
14 adenoma sebaceum 32 HP:0009720
15 renal cyst 32 HP:0000107
16 shagreen patch 32 HP:0009721
17 cafe-au-lait spot 32 HP:0000957
18 gingival fibromatosis 32 HP:0000169
19 renal angiomyolipoma 32 HP:0006772
20 subependymal nodules 32 HP:0009716
21 achromatic retinal patches 32 HP:0009727
22 cardiac rhabdomyoma 32 HP:0009729
23 ependymoma 32 HP:0002888
24 cortical tubers 32 HP:0009717
25 chordoma 32 HP:0010762
26 optic nerve glioma 32 HP:0009734
27 subungual fibromas 32 HP:0009724

UMLS symptoms related to Tuberous Sclerosis 2:


seizures, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness

GenomeRNAi Phenotypes related to Tuberous Sclerosis 2 according to GeneCards Suite gene sharing:

26 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.86 DAPK1 MAPKAPK2 MTOR PKD1
2 Decreased viability GR00221-A-1 9.86 DAPK1 MTOR
3 Decreased viability GR00221-A-3 9.86 MAPKAPK2
4 Decreased viability GR00221-A-4 9.86 DAPK1 MTOR
5 Decreased viability GR00342-S-1 9.86 DAPK1 MTOR
6 Decreased viability GR00342-S-2 9.86 MTOR
7 Decreased viability GR00402-S-2 9.86 DAPK1 MAPKAPK2 MTOR PKD1
8 Decreased cell migration GR00055-A-1 9.72 DAPK1 MAPKAPK2 MTOR PKD1 TSC1
9 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.56 DAPK1 IRS1 MTOR PKD1
10 Decreased substrate adherent cell growth GR00193-A-2 9.55 DAPK1 MAPKAPK2 MTOR
11 Decreased substrate adherent cell growth GR00193-A-3 9.55 DAPK1 MAPKAPK2
12 Decreased viability with paclitaxel GR00179-A-1 9.02 IGF1 MTOR
13 Decreased viability with paclitaxel GR00179-A-2 9.02 IGF1 MTOR
14 Decreased viability with paclitaxel GR00179-A-3 9.02 MTOR

MGI Mouse Phenotypes related to Tuberous Sclerosis 2:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.29 DAPK1 IFNG IGF1 IRS1 MAPKAPK2 MTOR
2 homeostasis/metabolism MP:0005376 10.27 DAPK1 IFNG IGF1 IRS1 MAPKAPK2 MTOR
3 cardiovascular system MP:0005385 10.26 IFNG IGF1 IRS1 MAPKAPK2 MTOR NR1H2
4 mortality/aging MP:0010768 10.2 IFNG IGF1 IRS1 KCNA2 MAPKAPK2 MTOR
5 hematopoietic system MP:0005397 10.16 IFNG IGF1 IRS1 MAPKAPK2 MTOR NR1H2
6 endocrine/exocrine gland MP:0005379 10.13 IFNG IGF1 IRS1 MTOR NR1H2 PKD1
7 nervous system MP:0003631 10.11 DAPK1 IFNG IGF1 KCNA2 MAPKAPK2 MTOR
8 embryo MP:0005380 10.08 IFNG MAPKAPK2 MTOR PKD1 SERPINC1 TSC1
9 muscle MP:0005369 10.03 IFNG IGF1 IRS1 MAPKAPK2 MTOR NR1H2
10 liver/biliary system MP:0005370 10.02 IFNG IRS1 NR1H2 PKD1 SERPINC1 TSC1
11 neoplasm MP:0002006 9.95 IFNG IGF1 MAPKAPK2 NTHL1 PKD1 TSC1
12 normal MP:0002873 9.87 IFNG IGF1 MAPKAPK2 MTOR NR1H2 PKD1
13 renal/urinary system MP:0005367 9.86 DAPK1 IFNG IGF1 MTOR PKD1 SERPINC1
14 reproductive system MP:0005389 9.7 IFNG IGF1 NR1H2 PKD1 SERPINC1 TSC1
15 respiratory system MP:0005388 9.43 IFNG IGF1 KCNA2 MTOR PKD1 TSC1
16 skeleton MP:0005390 9.23 IFNG IGF1 IRS1 MAPKAPK2 MTOR NR1H2
Sources

Drugs & Therapeutics for Tuberous Sclerosis 2

About this section

Drugs for Tuberous Sclerosis 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 2, Phase 3,Phase 3,Phase 1 159351-69-6 6442177
2
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 53123-88-9 46835353 6436030 5284616
3
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1 22916-47-8 4189
4 Anti-Bacterial Agents Phase 2, Phase 3,Phase 3,Phase 1
5 Antibiotics, Antitubercular Phase 2, Phase 3,Phase 3,Phase 1
6 Immunosuppressive Agents Phase 2, Phase 3,Phase 3,Phase 1
7 Anti-Infective Agents Phase 2, Phase 3,Phase 3,Phase 1
8 Antifungal Agents Phase 2, Phase 3,Phase 3,Phase 1
9 Immunologic Factors Phase 2, Phase 3,Phase 3,Phase 1
10
Metformin Approved Phase 2 657-24-9 14219 4091
11
Gemcitabine Approved Phase 2 95058-81-4 60750
12
Vemurafenib Approved Phase 2 918504-65-1 23252090 42611257
13
Olaparib Approved Phase 2 763113-22-0 23725625
14
Palbociclib Approved, Investigational Phase 2 571190-30-2 11431660 5330286 5005498
15
Pertuzumab Approved Phase 2 145040-37-5, 380610-27-5 2540
16
Osimertinib Approved Phase 2 1421373-65-0
17
Adenosine Approved, Investigational Phase 2 58-61-7 60961
18
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
19
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
20
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
21
Trametinib Approved Phase 2 871700-17-3 11707110
22
Nivolumab Approved Phase 2 946414-94-4
23
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
24
Racepinephrine Approved Phase 2 329-65-7 838
25
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
26
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
27
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
28
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
29
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
30
Tremelimumab Investigational Phase 2 745013-59-6
31
Lapatinib Approved March 2007, Investigational Phase 2 388082-78-8, 231277-92-2 208908 9941095
32 Hypoglycemic Agents Phase 2
33 Antimetabolites, Antineoplastic Phase 2
34 Antimetabolites Phase 2
35 Protein Kinase Inhibitors Phase 2
36 Antiviral Agents Phase 2
37
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
38 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
39 tyrosine Phase 2
40 Epinephryl borate Phase 2
41
s 1 (combination) Phase 2
42 Maytansine Phase 2
43 Immunoconjugates Phase 2
44 Antibodies, Monoclonal Phase 2
45 Antibodies Phase 2
46 Antimitotic Agents Phase 2
47 Immunoglobulins Phase 2
48 Angiogenesis Modulating Agents Phase 2
49 Antineoplastic Agents, Phytogenic Phase 2
50 Angiogenesis Inhibitors Phase 2

Interventional clinical trials:

(show all 18)
# Name Status NCT ID Phase Drugs
1 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3 Everolimus;Placebo
2 Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) Completed NCT00790400 Phase 3 Everolimus (RAD001);Everolimus Placebo
3 Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations Completed NCT02352844 Phase 2 Everolimus
4 Metformin Combined With Chemotherapy for Pancreatic Cancer Completed NCT01210911 Phase 2 gemcitabine;erlotinib;metformin;placebo
5 Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T Completed NCT02332902 Phase 2 Everolimus
6 Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations Recruiting NCT03047213 Phase 2 Sapanisertib
7 PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03213678 Phase 2 PI3K/mTOR Inhibitor LY3023414
8 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;PI3K/mTOR Inhibitor LY3023414;Selumetinib Sulfate;Tazemetostat;Ulixertinib;Vemurafenib
9 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Recruiting NCT02465060 Phase 2 Adavosertib;Afatinib;Binimetinib;Capivasertib;Crizotinib;Dabrafenib;Dasatinib;Defactinib;FGFR Inhibitor AZD4547;Larotrectinib;Osimertinib;Palbociclib;PI3K-beta Inhibitor GSK2636771;Sapanisertib;Sunitinib Malate;Taselisib;Trametinib;Vismodegib
10 Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) Recruiting NCT03297606 Phase 2 Olaparib;Dasatinib;Nivolumab plus Ipilimumab;Axitinib;Bosutinib;Crizotinib;Palbociclib;Sunitinib;Temsirolimus;Erlotinib;Trastuzumab plus Pertuzumab;Vemurafenib plus Cobimetinib;Vismodegib
11 Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: My Own Specific Treatment Recruiting NCT02029001 Phase 2 Nilotinib (400 mg BID);Everolimus (10 mg QD);Sorafenib (400 mg BID);Lapatinib (1500 mg QD);Pazopanib (800 mg QD);Olaparib (300 mg BID)
12 Everolimus for Cancer With TSC1 or TSC2 Mutation Active, not recruiting NCT02201212 Phase 2 Everolimus
13 COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC Active, not recruiting NCT02484664 Phase 2 Celecoxib
14 A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies Completed NCT01470209 Phase 1 BKM120;Everolimus
15 Genetic Heterogeneity and Genotype-phenotype Correlation of Children and Adults With Tuberous Sclerosis Complex Recruiting NCT02654340
16 Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma Recruiting NCT02325505
17 Expanded Access for ABI-009 in Patients With Advanced Perivascular Epithelioid Cell Tumors (PEComa) and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation Available NCT03817515 ABI-009
18 Multi-center Clinical Study on the Diagnosis and Treatment Management of Rare Neurological Disease in Children Not yet recruiting NCT03649919

Search NIH Clinical Center for Tuberous Sclerosis 2

Sources

Genetic Tests for Tuberous Sclerosis 2

About this section

Genetic tests related to Tuberous Sclerosis 2:

# Genetic test Affiliating Genes
1 Tuberous Sclerosis 2 29 IFNG TSC2
Sources

Anatomical Context for Tuberous Sclerosis 2

About this section

MalaCards organs/tissues related to Tuberous Sclerosis 2:

41
Skin, Brain, Kidney, Heart, Lung, Liver, Eye
Sources

Publications for Tuberous Sclerosis 2

About this section

Articles related to Tuberous Sclerosis 2:

(show all 31)
# Title Authors Year
1
Novel Inflammatory Neuropathology in Immature Brain: (1) Fetal Tuberous Sclerosis, (2) Febrile Seizures, (3) I+-B-crystallin, and (4) Role of Astrocytes. ( 29103422 )
2017
2
Tuberous sclerosis-2 (TSC2) regulates the stability of death-associated protein kinase-1 (DAPK) through a lysosome-dependent degradation pathway. ( 21134130 )
2011
3
AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation. ( 20363874 )
2010
4
The G1556S-type tuberin variant suppresses tumor formation in tuberous sclerosis 2 mutant (Eker) rats despite its deficiency in mTOR inhibition. ( 18695678 )
2008
5
Tuberous sclerosis-2 tumor suppressor modulates ERK and B-Raf activity in transformed renal epithelial cells. ( 14612383 )
2004
6
Prostaglandin E2 mediates phosphorylation and down-regulation of the tuberous sclerosis-2 tumor suppressor (tuberin) in human endometrial adenocarcinoma cells via the Akt signaling pathway. ( 15579767 )
2004
7
Polycystic kidney disease as a result of loss of the tuberous sclerosis 2 tumor suppressor gene during development. ( 12547704 )
2003
8
Aberrant splicing in several human tumors in the tumor suppressor genes neurofibromatosis type 1, neurofibromatosis type 2, and tuberous sclerosis 2. ( 11888927 )
2002
9
A calmodulin binding site in the tuberous sclerosis 2 gene product is essential for regulation of transcription events and is altered by mutations linked to tuberous sclerosis and lymphangioleiomyomatosis. ( 11811958 )
2002
10
The tuberous sclerosis 2 gene product can localize to nuclei in a phosphorylation-dependent manner. ( 11703097 )
2001
11
Transformation of kidney epithelial cells by a quinol thioether via inactivation of the tuberous sclerosis-2 tumor suppressor gene. ( 11398196 )
2001
12
Genetic variants of the tuberous sclerosis 2 tumour suppressor gene in mouse t haplotypes. ( 10584558 )
1999
13
Mutation and polymorphism analysis in the tuberous sclerosis 2 (TSC2) gene. ( 10732801 )
1998
14
Loss of function of the tuberous sclerosis 2 tumor suppressor gene results in embryonic lethality characterized by disrupted neuroepithelial growth and development. ( 9861021 )
1998
15
Novel intragenic polymorphisms in the tuberous sclerosis 2 (TSC2) gene. Mutations in brief no. 184. Online. ( 10660335 )
1998
16
An EcoRV polymorphism in exon 40 of the tuberous sclerosis 2 (TSC2) gene. ( 9076719 )
1997
17
Identification of a leader exon and a core promoter for the rat tuberous sclerosis 2 (Tsc2) gene and structural comparison with the human homolog. ( 9250859 )
1997
18
The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis. ( 9045618 )
1997
19
A novel splice site associated polymorphism in the tuberous sclerosis 2 (TSC2) gene may predispose to the development of sporadic gangliogliomas. ( 9210877 )
1997
20
Expression of the tuberous sclerosis 2 gene product, tuberin, in adult and developing nervous system tissues. ( 9173918 )
1996
21
Localization of tuberous sclerosis 2 mRNA and its protein product tuberin in normal human brain and in cerebral lesions of patients with tuberous sclerosis. ( 8944308 )
1996
22
Comparative analysis and genomic structure of the tuberous sclerosis 2 (TSC2) gene in human and pufferfish. ( 8789450 )
1996
23
Suppression of tumorigenicity by the wild-type tuberous sclerosis 2 (Tsc2) gene and its C-terminal region. ( 8799170 )
1996
24
Comparative analysis and genomic structure of the tuberous sclerosis 2 (TSC2) gene in human and pufferfish. ( 8845853 )
1996
25
Alternative splicing of the tuberous sclerosis 2 (TSC2) gene in human and mouse tissues. ( 7558029 )
1995
26
Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific Rap1GAP activity. ( 7608212 )
1995
27
The tuberous sclerosis 2 gene is expressed at high levels in the cerebellum and developing spinal cord. ( 8562486 )
1995
28
Allelic loss at the tuberous sclerosis 2 locus in spontaneous tumors in the Eker rat. ( 7546222 )
1995
29
The mouse homologue of the human tuberous sclerosis 2 (TSC2) gene maps to chromosome 17, but does not fall within the tw18 or th20 deletions. ( 7601476 )
1995
30
Identification of tuberous sclerosis 2 messenger RNA splice variants that are conserved and differentially expressed in rat and human tissues. ( 8519695 )
1995
31
Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. ( 7972075 )
1994
Sources

Variations for Tuberous Sclerosis 2

About this section

UniProtKB/Swiss-Prot genetic disease variations for Tuberous Sclerosis 2:

75 (show top 50) (show all 51)
# Symbol AA change Variation ID SNP ID
1 TSC2 p.Leu292Pro VAR_005646 rs45517138
2 TSC2 p.Tyr407Asp VAR_005647 rs45517156
3 TSC2 p.Met449Ile VAR_005648 rs45443091
4 TSC2 p.Arg611Gln VAR_005650 rs28934872
5 TSC2 p.Arg611Trp VAR_005651 rs45469298
6 TSC2 p.Leu826Met VAR_005652 rs45517238
7 TSC2 p.Arg905Gln VAR_005653 rs45517259
8 TSC2 p.Arg905Trp VAR_005654 rs45517258
9 TSC2 p.Asp1084Glu VAR_005655 rs45517286
10 TSC2 p.Arg1200Trp VAR_005656 rs45438205
11 TSC2 p.Pro1227Leu VAR_005657
12 TSC2 p.Arg1240Trp VAR_005658
13 TSC2 p.Asp1295Val VAR_005659
14 TSC2 p.Tyr1549Cys VAR_005661 rs45517355
15 TSC2 p.Asn1643Ile VAR_005663 rs45517380
16 TSC2 p.Tyr1650Cys VAR_005664 rs45501091
17 TSC2 p.Asp1690Tyr VAR_005665 rs137854882
18 TSC2 p.Ala1712Glu VAR_005666
19 TSC2 p.Leu1750Phe VAR_005667 rs45459299
20 TSC2 p.Cys227Tyr VAR_008020 rs45517122
21 TSC2 p.Asn331Lys VAR_008021 rs45517153
22 TSC2 p.Asn486Ile VAR_008022 rs45486599
23 TSC2 p.Pro816Leu VAR_008026 rs45517236
24 TSC2 p.Val1144Met VAR_008027 rs45517294
25 TSC2 p.Pro1315Ser VAR_008028 rs397514916
26 TSC2 p.Pro1709Leu VAR_008030 rs45517393
27 TSC2 p.Arg1743Gln VAR_008031 rs45507199
28 TSC2 p.His1773Pro VAR_008032 rs45517418
29 TSC2 p.Glu1783Gln VAR_008033
30 TSC2 p.Lys258Asn VAR_009417 rs137854875
31 TSC2 p.Arg261Pro VAR_009418 rs45502703
32 TSC2 p.Gly294Glu VAR_009422 rs45487497
33 TSC2 p.Leu361Pro VAR_009426 rs45517147
34 TSC2 p.Asn525Ser VAR_009432 rs45457694
35 TSC2 p.Lys599Met VAR_009435 rs45517202
36 TSC2 p.Ala614Asp VAR_009436 rs45454398
37 TSC2 p.Cys696Tyr VAR_009439 rs45486196
38 TSC2 p.Leu717Arg VAR_009440 rs45517214
39 TSC2 p.Met895Val VAR_009442 rs45470695
40 TSC2 p.Pro1497Arg VAR_009445 rs45497997
41 TSC2 p.Ser1498Asn VAR_009446 rs137854879
42 TSC2 p.His1620Tyr VAR_009448 rs45446901
43 TSC2 p.Asn1643Lys VAR_009449 rs45517381
44 TSC2 p.Asn1651Ser VAR_009450 rs45517382
45 TSC2 p.Pro1675Leu VAR_009451 rs45483392
46 TSC2 p.Asn1681Lys VAR_009452 rs45476793
47 TSC2 p.Ser1704Thr VAR_009453 rs45474691
48 TSC2 p.Arg1743Pro VAR_009454 rs45507199
49 TSC2 p.Leu1744Pro VAR_009455 rs45517413
50 TSC2 p.Ser1653Phe VAR_018603 rs45517383

ClinVar genetic disease variations for Tuberous Sclerosis 2:

6 (show top 50) (show all 4215)
# Gene Variation Type Significance SNP ID Assembly Location
1 TSC2 TSC2, 1-BP DEL, 5110A deletion Pathogenic
2 TSC2 NM_000548.4(TSC2): c.4642delC (p.Leu1548Cysfs) deletion Pathogenic rs137854083 GRCh37 Chromosome 16, 2135303: 2135303
3 TSC2 NM_000548.4(TSC2): c.4642delC (p.Leu1548Cysfs) deletion Pathogenic rs137854083 GRCh38 Chromosome 16, 2085302: 2085302
4 TSC2 NM_000548.4(TSC2): c.5024C> T (p.Pro1675Leu) single nucleotide variant Pathogenic rs45483392 GRCh37 Chromosome 16, 2137898: 2137898
5 TSC2 NM_000548.4(TSC2): c.5024C> T (p.Pro1675Leu) single nucleotide variant Pathogenic rs45483392 GRCh38 Chromosome 16, 2087897: 2087897
6 TSC2 NM_000548.4(TSC2): c.34A> T (p.Lys12Ter) single nucleotide variant Pathogenic rs45512692 GRCh37 Chromosome 16, 2098650: 2098650
7 TSC2 NM_000548.4(TSC2): c.34A> T (p.Lys12Ter) single nucleotide variant Pathogenic rs45512692 GRCh38 Chromosome 16, 2048649: 2048649
8 TSC2 NM_000548.4(TSC2): c.2056_2059dupTACT (p.Ser687Leufs) duplication Pathogenic rs137854337 GRCh37 Chromosome 16, 2121894: 2121897
9 TSC2 NM_000548.4(TSC2): c.2056_2059dupTACT (p.Ser687Leufs) duplication Pathogenic rs137854337 GRCh38 Chromosome 16, 2071893: 2071896
10 TSC2 NM_000548.4(TSC2): c.1513C> T (p.Arg505Ter) single nucleotide variant Pathogenic rs45517179 GRCh37 Chromosome 16, 2114342: 2114342
11 TSC2 NM_000548.4(TSC2): c.1513C> T (p.Arg505Ter) single nucleotide variant Pathogenic rs45517179 GRCh38 Chromosome 16, 2064341: 2064341
12 TSC2 NM_000548.4(TSC2): c.1832G> A (p.Arg611Gln) single nucleotide variant Pathogenic rs28934872 GRCh37 Chromosome 16, 2120572: 2120572
13 TSC2 NM_000548.4(TSC2): c.1832G> A (p.Arg611Gln) single nucleotide variant Pathogenic rs28934872 GRCh38 Chromosome 16, 2070571: 2070571
14 TSC2 NM_000548.4(TSC2): c.2150T> G (p.Leu717Arg) single nucleotide variant Pathogenic rs45517214 GRCh37 Chromosome 16, 2122294: 2122294
15 TSC2 NM_000548.4(TSC2): c.2150T> G (p.Leu717Arg) single nucleotide variant Pathogenic rs45517214 GRCh38 Chromosome 16, 2072293: 2072293
16 TSC2 NM_000548.4(TSC2): c.1432C> T (p.Gln478Ter) single nucleotide variant Pathogenic rs121964862 GRCh37 Chromosome 16, 2113043: 2113043
17 TSC2 NM_000548.4(TSC2): c.1432C> T (p.Gln478Ter) single nucleotide variant Pathogenic rs121964862 GRCh38 Chromosome 16, 2063042: 2063042
18 TSC2 NM_000548.4(TSC2): c.4508A> C (p.Gln1503Pro) single nucleotide variant Pathogenic/Likely pathogenic rs45516293 GRCh37 Chromosome 16, 2134966: 2134966
19 TSC2 NM_000548.4(TSC2): c.4508A> C (p.Gln1503Pro) single nucleotide variant Pathogenic/Likely pathogenic rs45516293 GRCh38 Chromosome 16, 2084965: 2084965
20 TSC2 NM_000548.4(TSC2): c.5238_5255del18 (p.His1746_Arg1751del) deletion Pathogenic rs137854218 GRCh37 Chromosome 16, 2138305: 2138322
21 TSC2 NM_000548.4(TSC2): c.5238_5255del18 (p.His1746_Arg1751del) deletion Pathogenic rs137854218 GRCh38 Chromosome 16, 2088304: 2088321
22 TSC2 NM_000548.4(TSC2): c.2714G> A (p.Arg905Gln) single nucleotide variant Pathogenic rs45517259 GRCh37 Chromosome 16, 2126143: 2126143
23 TSC2 NM_000548.4(TSC2): c.2714G> A (p.Arg905Gln) single nucleotide variant Pathogenic rs45517259 GRCh38 Chromosome 16, 2076142: 2076142
24 TSC2 NM_000548.4(TSC2): c.2713C> T (p.Arg905Trp) single nucleotide variant Pathogenic rs45517258 GRCh37 Chromosome 16, 2126142: 2126142
25 TSC2 NM_000548.4(TSC2): c.2713C> T (p.Arg905Trp) single nucleotide variant Pathogenic rs45517258 GRCh38 Chromosome 16, 2076141: 2076141
26 TSC2 NM_000548.4(TSC2): c.2713C> G (p.Arg905Gly) single nucleotide variant Pathogenic rs45517258 GRCh37 Chromosome 16, 2126142: 2126142
27 TSC2 NM_000548.4(TSC2): c.2713C> G (p.Arg905Gly) single nucleotide variant Pathogenic rs45517258 GRCh38 Chromosome 16, 2076141: 2076141
28 TSC2 NM_000548.4(TSC2): c.2355+2_2355+5delTAGG deletion Pathogenic rs137854250 GRCh37 Chromosome 16, 2122986: 2122989
29 TSC2 NM_000548.4(TSC2): c.2355+2_2355+5delTAGG deletion Pathogenic rs137854250 GRCh38 Chromosome 16, 2072985: 2072988
30 TSC2 NM_000548.4(TSC2): c.1322G> A (p.Trp441Ter) single nucleotide variant Pathogenic rs45515894 GRCh37 Chromosome 16, 2112562: 2112562
31 TSC2 NM_000548.4(TSC2): c.1322G> A (p.Trp441Ter) single nucleotide variant Pathogenic rs45515894 GRCh38 Chromosome 16, 2062561: 2062561
32 IFNG NM_000619.2(IFNG): c.115-484_115-457CA[12] NT expansion risk factor rs587776821 GRCh37 Chromosome 12, 68552496: 68552497
33 IFNG NM_000619.2(IFNG): c.115-484_115-457CA[12] NT expansion risk factor rs587776821 GRCh38 Chromosome 12, 68158716: 68158717
34 TSC2 NM_000548.4(TSC2): c.1070C> T (p.Ala357Val) single nucleotide variant Conflicting interpretations of pathogenicity rs150195368 GRCh37 Chromosome 16, 2110765: 2110765
35 TSC2 NM_000548.4(TSC2): c.1070C> T (p.Ala357Val) single nucleotide variant Conflicting interpretations of pathogenicity rs150195368 GRCh38 Chromosome 16, 2060764: 2060764
36 TSC2 NM_000548.4(TSC2): c.1100G> A (p.Arg367Gln) single nucleotide variant Benign/Likely benign rs1800725 GRCh37 Chromosome 16, 2110795: 2110795
37 TSC2 NM_000548.4(TSC2): c.1100G> A (p.Arg367Gln) single nucleotide variant Benign/Likely benign rs1800725 GRCh38 Chromosome 16, 2060794: 2060794
38 TSC2 NM_000548.4(TSC2): c.1318G> A (p.Gly440Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs45484298 GRCh37 Chromosome 16, 2112558: 2112558
39 TSC2 NM_000548.4(TSC2): c.1318G> A (p.Gly440Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs45484298 GRCh38 Chromosome 16, 2062557: 2062557
40 TSC2 NM_000548.4(TSC2): c.1340C> T (p.Ala447Val) single nucleotide variant Conflicting interpretations of pathogenicity rs45486591 GRCh37 Chromosome 16, 2112580: 2112580
41 TSC2 NM_000548.4(TSC2): c.1340C> T (p.Ala447Val) single nucleotide variant Conflicting interpretations of pathogenicity rs45486591 GRCh38 Chromosome 16, 2062579: 2062579
42 TSC2 NM_000548.4(TSC2): c.1458C> G (p.Asn486Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs200532154 GRCh37 Chromosome 16, 2114287: 2114287
43 TSC2 NM_000548.4(TSC2): c.1458C> G (p.Asn486Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs200532154 GRCh38 Chromosome 16, 2064286: 2064286
44 TSC2 NM_000548.4(TSC2): c.1747G> A (p.Ala583Thr) single nucleotide variant Benign/Likely benign rs1800729 GRCh37 Chromosome 16, 2120487: 2120487
45 TSC2 NM_000548.4(TSC2): c.1747G> A (p.Ala583Thr) single nucleotide variant Benign/Likely benign rs1800729 GRCh38 Chromosome 16, 2070486: 2070486
46 TSC2 NM_000548.4(TSC2): c.1819G> A (p.Ala607Thr) single nucleotide variant Benign/Likely benign rs45517203 GRCh37 Chromosome 16, 2120559: 2120559
47 TSC2 NM_000548.4(TSC2): c.1819G> A (p.Ala607Thr) single nucleotide variant Benign/Likely benign rs45517203 GRCh38 Chromosome 16, 2070558: 2070558
48 TSC2 NM_000548.4(TSC2): c.1939G> A (p.Asp647Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs45509392 GRCh37 Chromosome 16, 2121610: 2121610
49 TSC2 NM_000548.4(TSC2): c.1939G> A (p.Asp647Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs45509392 GRCh38 Chromosome 16, 2071609: 2071609
50 TSC2 NM_000548.4(TSC2): c.2476C> A (p.Leu826Met) single nucleotide variant Conflicting interpretations of pathogenicity rs45517238 GRCh37 Chromosome 16, 2124321: 2124321
Sources

Expression for Tuberous Sclerosis 2

About this section
Search GEO for disease gene expression data for Tuberous Sclerosis 2.
Sources

Pathways for Tuberous Sclerosis 2

About this section

Pathways related to Tuberous Sclerosis 2 according to GeneCards Suite gene sharing:

(show all 47)
# Super pathways Score Top Affiliating Genes
1
Akt Signaling 64
Show member pathways
 13.3 IGF1 IRS1 MAPKAPK2 MTOR TSC1 TSC2
2
Human cytomegalovirus infection 37
Show member pathways
 12.95 CALM1 MAPKAPK2 MTOR TSC1 TSC2
3
p70S6K Signaling 64
Show member pathways
 12.94 IGF1 IRS1 MTOR TSC1 TSC2
4
PI3K-Akt signaling pathway 37
Show member pathways
 12.88 IGF1 IRS1 MTOR TSC1 TSC2
5
TNFR1 Pathway 64
Show member pathways
 12.86 CALM1 DAPK1 IGF1 IRS1 MTOR TSC2
6
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 12.77 CALM1 IGF1 IRS1 MTOR TSC1 TSC2
7
NFAT and Cardiac Hypertrophy 64
Show member pathways
 12.76 CALM1 IGF1 IRS1 MAPKAPK2 MTOR
8
Pathways in cancer 37
12.73 CALM1 DAPK1 IFNG IGF1 MTOR
9
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 12.63 CALM1 IRS1 MTOR TSC2
10
Development HGF signaling pathway 22
Show member pathways
 12.62 CALM1 IRS1 MAPKAPK2 MTOR
11
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.57 CALM1 IGF1 MTOR TSC2
12
Glioma 37
Show member pathways
 12.55 CALM1 IGF1 IRS1 MTOR TSC1 TSC2
13
Angiopoietin Like Protein 8 Regulatory Pathway 1
Show member pathways
 12.42 IRS1 MTOR TSC1 TSC2
14
mTOR signaling pathway (KEGG) 65
Show member pathways
 12.36 IGF1 IRS1 MTOR TSC1 TSC2
15
mTOR signalling 66
Show member pathways
 12.32 IRS1 MTOR TSC1 TSC2
16
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.27 IGF1 IRS1 MTOR TSC1 TSC2
17
Development IGF-1 receptor signaling 22
Show member pathways
 12.21 IGF1 IRS1 MTOR TSC1 TSC2
18
AMPK Enzyme Complex Pathway 64
Show member pathways
 12.13 IRS1 MTOR TSC1 TSC2
19
MicroRNAs in cardiomyocyte hypertrophy 1
Show member pathways
 12.07 CALM1 IGF1 MTOR
20
Integrated Breast Cancer Pathway 1
12.06 IRS1 MTOR TSC1 TSC2
21
Autophagy Pathway 65
Show member pathways
 12.04 MTOR TSC1 TSC2
22
Brain-Derived Neurotrophic Factor (BDNF) signaling pathway 1
12.02 IRS1 MTOR TSC2
23
Transcription Androgen Receptor nuclear signaling 22
Show member pathways
 12.02 IGF1 IRS1 MTOR TSC2
24
IL-2 Signaling Pathway 1
Show member pathways
 11.98 IFNG IRS1 MAPKAPK2
25
Immune response IFN gamma signaling pathway 22
Show member pathways
 11.98 CALM1 DAPK1 IFNG IGF1 MTOR
26
Translation Translation regulation by Alpha-1 adrenergic receptors 22
Show member pathways
 11.92 CALM1 MTOR TSC2
27
Immune response Function of MEF2 in T lymphocytes 22
Show member pathways
 11.92 CALM1 IGF1 IRS1 MTOR TSC2
28
Insulin resistance 37
Show member pathways
 11.86 IRS1 MTOR NR1H2
29
Glioblastoma Multiforme 64
11.86 IGF1 MTOR TSC1 TSC2
30
Cellular senescence (KEGG) 37
11.86 CALM1 MAPKAPK2 MTOR TSC1 TSC2
31
Senescence and Autophagy in Cancer 1
11.85 IFNG IGF1 MTOR
32
HIF-1 signaling pathway 37
11.81 IFNG IGF1 MTOR
33
TP53 Regulates Metabolic Genes 66
11.73 MTOR TSC1 TSC2
34
Longevity regulating pathway 37
Show member pathways
 11.73 IGF1 IRS1 MTOR TSC1 TSC2
35
Wnt Signaling Pathway Netpath 1
11.51 MTOR TSC1 TSC2
36
Autophagy - animal 37
11.46 DAPK1 IRS1 MTOR TSC1 TSC2
37
mTOR signaling pathway (Pathway Interaction Database) 1
11.41 IRS1 MTOR TSC1 TSC2
38
Type I Interferon Signaling Pathways 65
Show member pathways
 11.41 IFNG IRS1 MAPKAPK2 MTOR TSC1 TSC2
39
LKB1 signaling events 1
11.38 MTOR TSC1 TSC2
40
BDNF-TrkB Signaling 1
11.26 MTOR TSC1 TSC2
41
G-protein signaling_Cross-talk between Ras-family GTPases 22
11.26 CALM1 IGF1 IRS1 MAPKAPK2 MTOR
42
Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling 1
11.2 IGF1 IRS1 MTOR
43
Follicle Stimulating Hormone (FSH) signaling pathway 1
11.13 MTOR TSC2
44
EGFR Transactivation by Gastrin 66
Show member pathways
 11.11 IGF1 MTOR
45
p38 signaling mediated by MAPKAP kinases 1
10.98 MAPKAPK2 TSC2
46
4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression 1
10.92 MTOR TSC1
47
Insulin signalling in human adipocytes (normal condition) 1
Show member pathways
 10.86 IRS1 MTOR
Sources

GO Terms for Tuberous Sclerosis 2

About this section

Cellular components related to Tuberous Sclerosis 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 TSC1-TSC2 complex GO:0033596 8.62 TSC1 TSC2

Biological processes related to Tuberous Sclerosis 2 according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.84 IFNG IGF1 MTOR NR1H2
2 peptidyl-serine phosphorylation GO:0018105 9.7 MAPKAPK2 MTOR PKD1
3 cell cycle arrest GO:0007050 9.67 IFNG MTOR PKD1
4 mRNA stabilization GO:0048255 9.51 MAPKAPK2 MTOR
5 positive regulation of glycogen biosynthetic process GO:0045725 9.48 IGF1 IRS1
6 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.46 CALM1 MTOR
7 negative regulation of macroautophagy GO:0016242 9.43 MTOR TSC1
8 positive regulation of cell growth involved in cardiac muscle cell development GO:0061051 9.4 IGF1 MTOR
9 positive regulation of protein import into nucleus, translocation GO:0033160 9.37 IFNG IGF1
10 response to insulin GO:0032868 9.33 IRS1 MTOR TSC1
11 anoikis GO:0043276 9.32 MTOR TSC2
12 negative regulation of cell size GO:0045792 9.26 MTOR TSC1
13 negative regulation of insulin receptor signaling pathway GO:0046627 9.13 IRS1 TSC1 TSC2
14 insulin-like growth factor receptor signaling pathway GO:0048009 8.8 IGF1 IRS1 TSC2

Molecular functions related to Tuberous Sclerosis 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.47 CALM1 DAPK1 IFNG IGF1 IRS1 KCNA2
2 calmodulin-dependent protein kinase activity GO:0004683 9.32 DAPK1 MAPKAPK2
3 insulin receptor binding GO:0005158 9.26 IGF1 IRS1
4 phosphatidylinositol 3-kinase binding GO:0043548 9.16 CALM1 IRS1
5 insulin-like growth factor receptor binding GO:0005159 8.96 IGF1 IRS1
Sources

Sources for Tuberous Sclerosis 2

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....